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Regulators of G protein signaling (RGS) proteins accelerate the
GTPase activity of Ga protein subunits in vitro, negatively regu-
lating G protein-coupled receptor signaling. The physiological role
of mammalian RGS proteins is largely unknown. The RGS family
member rgs2 was cloned as an immediate early response gene
up-regulated in T lymphocytes after activation. To investigate the
role of RGS2 in vivo, we generated rgs2-deficient mice. We show
that targeted mutation of rgs2 in mice leads to reduced T cell
proliferation and IL-2 production, which translates in an impaired
antiviral immunity in vivo. Interestingly, rgs22/2 mice also display
increased anxiety responses and decreased male aggression in the
absence of cognitive or motor deficits. RGS2 also controls synaptic
development and basal electrical activity in hippocampal CA1
neurons. Thus, RGS2 plays an important role in T cell activation,
synapse development in the hippocampus, and emotive behaviors.
G protein-coupled receptors (GPCR) control fundamentalcellular processes ranging from embryogenesis and neuro-
transmitter release to cell survival, proliferation, and differen-
tiation. Heterotrimeric G proteins are composed of a, b, and g
subunits that relay GPCR stimulation to downstream signaling
pathways (1). On ligand binding, GPCR undergoes conforma-
tion changes of its intracellular loops that promote the exchange
of GDP for GTP on Ga and the subsequent dissociation of Ga
and Gbg. Both GTP-bound Ga and free Gbg propagate the
signal through interactions with downstream effectors. Deacti-
vation of GPCR signaling depends on the rate of Ga GTP
hydrolysis.
Studies of GPCR desensitization have led to the discovery of
a large and evolutionarily conserved family of GTP-activating
(GAP) factors for Ga termed ‘‘regulators of G protein signaling’’
(RGS). RGS proteins share an RGS domain ('120 amino acids)
capable of accelerating Ga-dependent GTP hydrolysis and the
conversion of active GTP-bound Ga to its inactive GDP-bound
form (2–7). The first RGS identified was the yeast protein Sst2,
isolated in a screen for mutants that failed to down-regulate the
GPCR-mediated response to mating pheromone (8–9). Over 20
mammalian RGS proteins have been identified (7, 10). Recently
it has been shown that RGS9–1 controls the photosensitization
response in the mouse eye (11). Axin, which contains a RGS
domain, negatively regulates the Wnt-signaling pathway, and
axin-mutant mice display defects in embryonic axis formation
(12). However, Axin has no detectable GAP activity for Ga (10).
The physiological roles of other mammalian RGS proteins are
yet to be established.
The RGS family member rgs2 was cloned as an early response
gene up-regulated in activated T cells (13–14). RGS2 is also
up-regulated in central nervous system (CNS) neurons after
stimuli that evoke long-term neuronal plasticity (15–16). In vitro,
RGS2 interacts with Gaq/11 and stimulates its GTPase activity
(17–18), and RGS2 overexpression in cells inhibits Gai- (15) and
Gas-dependent (19) signaling. To investigate the role of RGS2
in vivo, we generated rgs2-deficient mice. rgs2 deficiency in mice
leads to impaired T cell activation in vitro and in vivo. Interest-
ingly, mice lacking RGS2 also exhibit reduced male aggressive
behavior and increased anxiety, whereas morphological and
electrophysiological analyses indicate a role for RGS2 in hip-
pocampal CA1 neuron function.
Materials and Methods
rgs2 Mutant Mice. RGS2 exons 4 and 5 encoding the RGS
domain were replaced with PGK-NeoR in antisense orienta-
tion. G418-resistant E14K embryonic stem (ES) cells were
screened by PCR and Southern blot for homologous
recombination. Targeted ES cell clones were injected into
C57BLy6 blastocysts and heterozygous rgs-21/2 mice obtained
by mating chimeras with C57BLy6J mice. PCR primers: wild-
type allele (59-CCGAGTTCTGTGAAGAAAACATTG39;
59GGGACTCCTGGTCTCATGTAGCAT39) and mutant al-
lele (59-GCTAAAGCGCATGCTCCAGAC-39; 59-GGCCCA-
CATTTACACGAACC-39). All experiments were carried out
by using littermate mice on a C57BLy6J background (F5
generation), and mice were maintained in accordance with
institutional guidelines.
Immunocytometry. Single-cell suspensions of thymi, lymph nodes,
and spleens were stained with FITC-, phycoerythrin-, or biotin-
conjugated Abs reactive to CD3«, TCRab, CD4, CD8, CD25,
CD44, CD28, CD69, CD11b (Mac-1), CD11c, B220, CD43,
sIgM, sIgD, or Gr-1. Biotinylated antibodies were visualized by
using streptavidin-RED670. Samples were analyzed by flow
cytometry by using a FACScan (Becton Dickinson).
T and B Cell Assays. For proliferation assays, freshly isolated T cells
were activated with PMA (10 ngyml, phorbol myristate acetate)
plus Ca12 ionophore (100 ngyml, ionomycin), soluble anti-CD3«
(0.1–1 mgyml, clone 145–2C11), anti-CD28 (0.02–0.2 mgyml,
clone 37.51), or recombinant mouse IL-2 (50 unitsyml) in
triplicate for 12, 24, 48, 72, or 120 h, followed by a 12-h pulse with
[3H]thymidine (1 m Ciyml). Cytokine production was deter-
mined by ELISA. For B cell analysis, splenic B lymphocytes were
purified (90–95% B2201 cells) by negative magnetic sorting and
activated with various stimuli. Basal serum Ig levels (IgM, IgG1,
IgG2a, IgG2b, IgG3, and IgA) were determined by ELISA (20).
For lymphocytic choriomeningitis virus (LCMV) infections,
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mice were infected with LCMV (700 plaque-forming units, s.c.)
into the hind footpad. Cellular infiltration was measured daily as
described (21).
Behavior Studies. Four- to five-month-old sex-matched littermate
mice were examined for neuromotor functions (22): vibrissae,
eyes, rearingysupportystanding, muscle tone, tail hanging-
induced turns and limbsydigits extension, ear reflex, eye blink
and pupillary response to light, sweetybitter tasting acceptancey
rejection, and orientation toward sound. Circadian and open-
field activities (i.e., cage crosses, total distance, vertical move-
ments) were measured in cages fitted with infrared sensors.
Exploration test was performed by putting the mice in the center
of a white disk (183-cm diameter), with or without objects
distributed in four quadrants. The mice were video tracked
(seven trials). Fecal pellets and rears were counted. Motor
coordination was analyzed by a rotating rod task. For a balance
task, a mouse was held by the tail and allowed to grasp a
suspended horizontal wooden rod (3 mm Ø) with its hind limbs,
with recording of the time for the mouse to pull itself into
balance and the number of falls.
Mice were studied in a spatial water maze for 7 days with a
hidden platform in the southwest quadrant (22). On day 7, a
final probe trial (60 s in the pool without platform) was
applied. From day 8 to 16, tests were reassumed with the
platform moved to the northeast quadrant (reversal, 2 trials
per day). Time to find the platform and total distance were
measured. In the T-maze test, on day 1 the mice were placed
in an empty maze for 10 min with access only to its central and
right arms. Several objects were placed as cues around the
maze. On day 2, each subject was again placed in the T-maze
and given access to the left arm of the maze. The mice were
observed for 5 min, with recording of time spent in the new
area and first choice. Step-down avoidance test was also
carried out, in which the mice were required to remember that
prior stepping off a safe platform resulted in a foot shock (1
s, 0.12 mA). Latency on the platform was recorded in each
trial. Aggression was tested by using displacement from a
plastic tube (30 cm long and 3.05 cm Ø). A rgs22/2 and
littermate control mouse were released into either end of the
tube, with the first mouse to exit being deemed the ‘‘loser,’’
that is, this mouse was deemed to be the less aggressive of the
two. For lightydark preference tests, cages were divided into
dark and light halves and the time spent by each mouse in each
half measured.
Electrophysiology. Electophysiology studies were carried out as
described (23). Single hippocampal slices (400 mm) were
superfused with artificial cerebrospinal f luid (2 mlymin; sat-
urated with 95% O2 and 5% CO2 at 30°C). Field potentials
were sampled at 10 kHz and analyzed with PCLAMP6 software
(Axon Instruments, Foster City, CA). Field excitatory postsyn-
aptic potentials (EPSP) were recorded with a micropipette
(2–4 MV) placed in the stratum radiatum of CA1 area.
Stimulation was delivered at Schaffer collateral. Test stimulus
frequency was 0.1 Hz. The tetanic stimulation consisted of four
trains of 100-Hz stimulation lasting 500 ms at 10-s intervals.
EPSP slope was calculated from linear regression of the rising
phase 10–65% of the peak response. The baseline value of
EPSP slope was that from the first 5-min period and was
defined as 100%. Inputyoutput relationship was constructed
by plotting the amplitude of presynaptic volley (input) vs.
EPSP slope (output).
Results and Discussion
rgs2 Gene Targeting. The rgs2 locus was inactivated in ES cells by
replacing exons 4 and 5 corresponding to the RGS domain (Fig.
1A). Chimeric mice were bred to obtain germ-line transmission
of the mutated rgs2 allele (Fig. 1 B and C). The rgs2 mutation
proved to be null, as shown by Northern blot analyses of brain
tissue (Fig. 1D). rgs22/2 mice were born at the expected Men-
delian frequency, were fertile, and displayed normal growth. No
anatomical or histological abnormalities were observed. Differ-
entiation of all hematopoietic lineages, including neutrophils,
macrophages, erythrocytes, and platelets, was normal in rgs22/2
mice.
Fig. 1. Generation of rgs2-deficient mice. (A) rgs2 targeting vector. (B)
Southern blot (see 39 flanking probe in A) from rgs2 mutant ES cell clones.
Wild-type (WT) and mutant (KO) bands are shown. (C) Genotyping of rgs2
mice. WT and KO PCR primers are shown in A (arrows). Loss of the wild-type
rgs2 allele was confirmed by genomic Southern blot. (D) Northern blot analysis
of brain mRNA from rgs2 WT (1y1), heterozygous (1y2), and KO (2y2) mice
(full-length rgs2 cDNA probe).











Defective Proliferation and IL-2 Production by rgs22/2 T Cells. Be-
cause RGS2 expression is induced in activated T cells after TCR
engagement or stimulation by mitogens such as ConA or PMA
plus Ca21 ionophore (PMA 1 Iono) (ref. 14 and data not
shown), we determined whether RGS2 plays a role in T cell
activation. rgs22/2 mice displayed normal numbers and subsets
of CD41 and CD81 T cells and B cells in lymphoid organs (Fig.
2A). The surface levels of TCRab, CD3, CD4, CD8, CD28,
CD45, CD5, H2Kb, CD44, LFA1, CD25, and CD69 on both
splenic and lymph node peripheral CD41 and CD81 T cells were
comparable in rgs21/2 and rgs22/2 mice (not shown). To examine
peripheral T cell function, T cells from the lymph nodes of
rgs21/2 and rgs22/2 littermates were stimulated with anti-CD3«
mAb, anti-CD3« plus anti-CD28 mAbs, or PMA plus Ca21-
ionophore. The proliferation in vitro of rgs22/2 T cells was
significantly reduced in response to TCR engagement, a deficit
that could not be overcome by CD28 costimulation (Fig. 2B).
Consistent with the identification of RGS2 as an early response
gene in activated T cells (13–14), the proliferative defect was
most obvious at 24 h of stimulation. Induction and kinetics of
apoptosis were comparable among rgs21/2 and rgs22/2 T cells
(not shown). Thus, RGS2 acts as an immediate early gene
downstream of TCR activation in T cells.
In addition to their proliferative defect, rgs22/2 T cells pro-
duced significantly lower levels of the T cell growth factor IL-2
compared with controls (Fig. 2C). IL-2 insufficiency per se does
not explain the proliferative deficit because IL-2 supplementa-
tion did not restore proliferation to normal (Fig. 2B). The
high-affinity IL-2 receptor a chain (CD25) and the activation
markers CD69, CD44, ICAM1, and CTLA4 were up-regulated
to a normal extent and with normal kinetics in rgs22/2 T cells in
response to TCR engagement or mitogen treatment (not shown).
The functional defect in T cell proliferation (Fig. 2B) and
cytokine production (Fig. 2C) can also be observed in rgs22/2 T
cells treated with PMAyCa21 ionophore, a stimulus that by-
passes the proximal TCR signal. Consistent with this finding, the
kinetics and extent of early TCR-mediated signaling events,
including Ca21 mobilization, overall tyrosyl phosphorylation,
and activation of MAPK and SAPKyJNKs, were normal in
rgs22/2 lymph node T cells (not shown), suggesting that their
proximal TCR signaling pathways are intact.
With regards to B cells, rgs22/2 mice displayed normal num-
bers and differentiation (not shown). In vitro proliferation of
rgs22/2 B cells in response to treatment with anti-IgM Ab, the
F(ab9)2 fragment of the anti-IgM Ab, anti-CD40, or LPS was
similar to that of rgs21/2 B cells (Fig. 2D and data not shown).
Furthermore, baseline serum Ig levels were equivalent in rgs22/2
and rgs21/2 mice. Thus, RGS2 is not required for B cell
activation. Our results show that antigen receptor-triggered
RGS2 expression in T cells is required for proliferation and IL-2
production.
Chemokines are critical regulators of T cell function, signaling
via GPCRs expressed on the surface of resting and activated T
cells (24). It has also been shown that overexpression of RGS-
family members in cell lines can modulate chemokine receptor
signaling (18). However, no differences were observed between
both resting and preactivated (6-h activation with anti-CD3«
Fig. 2. Impaired proliferation and IL-2 production by rgs22/2 T cells. (A)
Normal populations of CD41 and CD81 T cells and B2201 B cells in lymph nodes
of rgs22/2 mice. Numbers in each quadrant represent percentages of each
subset. (B) Proliferation. Lymph node T cells (2 3 105ywell) from rgs22/2 and
rgs21/2 mice were activated by using PMA [10 ngyml]1Ca12-ionophore [100
ngyml], TCR stimulation [anti-CD3a mAb (0.1 mgyml)] with and without CD28
costimulation [anti-CD28 mAb (0.02 mgyml)] or IL-2 [50 unitsyml]. Results are
shown as mean [3H]thymidine uptake 6 SD. Difference in proliferation be-
tween rgs21/2 and rgs22/2 T cells was statistically significant (t test, P , 0.05).
(C) IL-2 production. Lymph node T cells were activated as above, and IL-2 was
measured by ELISA at 24 and 48 h poststimulation. Mean values of IL-2
production 6 SD are shown. (D) Activation of B cells. Purified splenic B cells
(1 3 105ywell) were incubated in triplicate for 24 and 48 h in medium alone
(None) or medium containing anti-IgM (20 mgyml), anti-IgM (Fab9)2 (15 mgyml)
with or without anti-CD40 (5 mgyml). Results are shown as mean [3H]thymi-
dine uptake 6 SD.
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before chemokine treatment) rgs21/2 and rgs22/2 CD41 or
CD81 T cells in either proliferation or cell migration in response
to the chemokines SDF-1a, RANTES, or MIP-1a (not shown).
These results do not preclude regulation by RGS2 of T cell
responsiveness to signals mediated by other chemokine recep-
tors. Furthermore, rgs21/2 and rgs22/2 T lymphocytes showed
comparable responses to the GPCR agonists lysophosphatidic
acid, histamine, and adenosine (not shown). The GPCRs whose
functions are under RGS2 control in T cells remain to be
identified.
Impaired Immunity in rgs22/2 Mice. To determine whether RGS2
plays a role in T cell responses in vivo, rgs21/2 and rgs22/2 mice
were injected in the footpad with LCMV (21). rgs21/2 mice
developed an effective LCMV-induced footpad swelling reaction
starting from day 6 postinfection (Fig. 3). In contrast, the
footpad swelling reaction was significantly decreased and de-
layed in rgs22/2 mice, indicating that RGS2 expression is re-
quired for an efficient antiviral response in vivo. Thus, the in vitro
deficit in proliferation and IL-2 production by rgs22/2 T cells
translates into an impaired anti-virus response in vivo, indicating
that RGS2 expression is physiologically relevant for normal T
cell function. These results provide the first genetic evidence that
RGS proteins play a role in the activation of lymphocyte.
RGS2 Controls Male Aggression and Anxiety. During our evaluation
of the mutant mice, we noted unusual fighting between male
rgs21/2 and rgs22/2 littermates that sometimes resulted in severe
injuries. Stimuli triggering long-term plasticity in the CNS induce
the up-regulation of RGS2 in the hippocampus, cortex, caudate
putamen, striatum, and amygdala (15–16). Because these regions
regulate a variety of behavioral pathways, we investigated
whether RGS2 plays a role in CNS function. We first determined
whether RGS2 deficiency in mice leads to alterations in motor
functions. Both rgs22/2 and rgs21/2 littermate mice showed
normal motor responses (tests listed in Materials and Methods).
Circadian activity was normal in the mutant mice (Fig. 4A), as
was exploratory behavior during two independent open field and
exploration tests (not shown). rgs22/2 mice also exhibited ap-
propriate performances in rotating rod (Fig. 4B) and balance
tests (not shown), confirming the integrity of the neurological
pathways responsible for motor coordination and balance. Spa-
tial and conditional learning, as determined by the hidden
platform, water maze, and passive avoidance tests, were com-
parable between rgs22/2 and rgs21/2 littermates. Long-term
potentiation in the Schaffer collateral CA1 pathway of individual
hippocampus slices was also equivalent in rgs22/2 and rgs21/2
mice (Fig. 4C). These data show that RGS2 deficiency has no
apparent effect on motor responses, circadian activity, explor-
atory behavior, motor coordination, or spatial learning and
memory.
Social dominance and territorial aggression are well-
characterized behaviors in male mice (25). Intriguingly, rgs22/2
male mice exhibited significantly reduced aggressive behavior
compared with their rgs21/2 littermates, whereas the aggressive
behavior of rgs22/2 female mice was normal (Fig. 5A). Because
aggression correlates with anxiety (25), we subjected rgs22/2
male mice to the lightydark preference test. rgs22/2 mice showed
a greater preference for the dark compared with rgs21/2 control
littermates (Fig. 5B), indicating increased anxiety. Consistent
with this behavioral phenotype, rgs22/2 mice were found to drop
significantly more fecal pellets than rgs21/2 littermates during
the lightydark preference test (2.3 6 0.6 vs. 0.8 6 0.3 pellets) and
Fig. 3. Reduced LCMV-induced footpad swelling in rgs22/2 mice. Mice were
infected in the footpad with LCMV and swelling measured. Average footpad
swelling (percentage increase compared with footpads thickness before in-
fection) of six animals per group.
Fig. 4. Normal circadian activity, motor functions, and long-term potentia-
tion (LTP) in rgs22/2 mice. (A) Circadian activity was monitored during a 24-h
period (12-h lightydark cycles). Mean crosses accumulated per 30-min inter-
vals 6 SD are shown. (B) Normal motor function in a rotarod test. Mean values
of retention times (latency) 6 SD are shown. Trials indicate a stepwise increase
in rotarod speed (10–40 rpm, 5-rpm increase per trial). (C) Tetanus-induced
LTP in CA1 neurons. Averaged normalized field EPSP (fEPSP) slope measure-
ments obtained from 11 hippocampus slices of 4 rgs21/2 and 4 rgs22/2 mice.











exploration test (3.5 6 0.6 vs. 1.3 6 0.6 pellets). In addition,
rgs22/2 mice exhibited an increased response to acoustic star-
tling. These data show that RGS2 controls neuronal circuits for
aggression and anxiety.
RGS2 Role in Synapse Development and Basal Electrical Activity of
Hippocampal CA1 Neurons. Fear and anxiety usually involve the
amygdala, and certain components of fear can be affected by
hippocampal inputs into the amygdala (26). Neurons from the
CA1 region of the hippocampus project to the amygdala and
removal of the hippocampus affects fear-based behavior (27).
Moreover, it has also been proposed that RGS2 can regulate the
activity of the G protein-coupled metabotropic glutamate re-
Fig. 5. RGS2 regulates male aggression and anxiety. (A) Reduced male
aggressive behavior. Aggression was measured in paired groups of male or
female rgs22/2 and rgs21/2 mice by using a replacement test. Results repre-
sented as percentages of displacement per group (‘‘wins’’). Eighteen trials
were carried out for each group. (B) Increased anxiety. The anxiety response
was measured by using a darkylight preference test. Note the increased
preference for the dark environment in rgs22/2 mice. The difference in mean
darkylight latency 6 SD was statistically significant (t test; P , 0.05).
Fig. 6. Reduced spine density in CA1 hippocampal neurons of rgs22/2 mice. (A–D) Histology of hippocampus of rgs21/2 (A and B) and rgs22/2 (C and D) mice.
Blue lines demarcate the CA1 neuron region. Normal structure of the CA1 region in rgs22/2 mice. Golgi–Cox staining, 34 and 3200. (E) Reduced numbers of spines
in rgs22/2 CA1 neurons. Densities (spinesy10 mm 6 SD) of apical and basilar spines were determined by camera lucida. Differences in apical and basilar spine
densities were statistically significant (t test, P , 0.005).
Fig. 7. Impaired basal electric activity in CA1 neurons of rgs22/2 mice. (A and
B) Reduction of inputyoutput relationship in CA1 pathway in rgs22/2 mice.
Superimposed recordings of CA1 field excitatory postsynaptic potentials
(fEPSP) evoked by electrical stimulation of Schaffer collateral input. Input:
peak amplitude of presynaptic volley. Output: field EPSP slope measured at
10–65% rising phase of EPSP. Data are from seven hippocampus slices of four
rgs21/2 and four rgs22/2 mice.
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ceptor 1, a receptor implicated in long-term synaptic plasticity in
the hippocampus (28). Detailed examination of rgs22/2 mice
revealed that the number of neurons in the hippocampus (Fig.
6 A–D), in other brain nuclei, the brainstem, cerebellum, and
cortex (not shown) were not affected by RGS2 deficiency.
Interestingly, whereas dendritic morphology and branching were
comparable among cortical neurons of rgs21/2 and rgs22/2 mice,
hippocampal CA1 neurons of rgs22/2 mice showed a significant
decrease in the density of apical and basilar spines compared
with those of rgs21/2 control littermates (Fig. 6E). The number
of spines correlates with synapse numbers and neuronal plastic-
ity (29). Importantly, the morphological deficit in spine numbers
of rgs22/2 CA1 neurons correlated with significantly reduced
electrical inputyoutput relationship in these cells (Fig. 7 A and
B). These data show that RGS2 has a role in synaptic develop-
ment and basal electrical activity of hippocampal CA1 neurons.
Alterations in aggressive behavior and fear responses are
important manifestations in highly prevalent psychiatric disor-
ders such as depression or addictive behaviors. Because these
disorders are responsible for a large social-economic burden, it
is critical to identify gene products potentially involved in the
initiation andyor progression of these behavioral ‘‘traits’’ into
clinically manifest ‘‘disease.’’ Multiple G protein-coupled recep-
tors can regulate these behaviors, and pharmacological drugs
that modulate these receptors have been developed to mitigate
anxiety disorders and aggression. Our study provides genetic
evidence that loss of a molecular regulators of G-protein sig-
naling, RGS2, leads to impaired synaptic development in the
hippocampus, reduced male aggressive behavior, and increased
fear. Thus, RGS-family member such as RGS2 could be involved
in the genetic predisposition to human neuropsychiatric disor-
ders and could be potential targets for the generation of novel
neuropharmacological drugs. rgs22/2 mice also provide a useful
animal model to elucidate molecular mechanisms of fear and
male aggression.
G protein-coupled receptors regulate fundamental processes
of development, cell activation, and behavior. The present study
shows that RGS2, a member of the RGS family, has important
roles in T cell proliferation and IL-2 production. The T cell
activation deficit observed in vitro translates into an impaired
anti-virus response in vivo, indicating that RGS2 is physiologi-
cally relevant for normal T cell function and the establishment
of an effective antiviral immune response. In addition, mice
lacking RGS2 exhibit significantly reduced aggressive behavior
and increased anxiety in the absence of any measured cognitive
and motor deficits. Furthermore, morphological and electro-
physiological analyses indicate that RGS2 expression is required
for the generation of synaptic plasticity in hippocampal CA1
neurons. Thus, RGS2 is a critical regulator of T cell activation,
neuronal function, and emotive fear, and aggression in vivo.
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